Hyperbare Zuurstoftherapie: Rapid Assessment - KCE

More documents

Recommendations

Info

28 Hyperbaric Oxygenation Therapy <strong>KCE</strong> Reports 74 No direct effect on minor amputations was found (see Figure 12), but it can be anticipated that the avoidance of major amputations results in an increase of minor amputations, indicating treatment success. One small trial (n=16) concerned venous ulcers and only suggested a significant benefit of HBOT at six weeks (reduction in ulcer size). For arterial and pressure ulcers not satisfactory trials were identified in this review. The authors, however, express cautious interpretation of these results in view of the small number of patients included in those trials. Forest plots illustrating these findings are shown in Figure 10 to Figure 13. Figure 10. Diabetic ulcers: Major amputations Source: Kranke et al. 32 Figure 11. Diabetic ulcers: Major amputations subgroups by use of sham Source: Kranke et al. 32
<strong>KCE</strong> Reports 74 Hyperbaric Oxygenation Therapy 29 Figure 12. Diabetic ulcers: Minor amputations Source: Kranke et al. 32 Figure 13. Venous ulcers: Wound size reduction at end treatment (six weeks). Favourable result is indicated by increased relative risk since the outcome is wound size reduction. Source: Kranke et al. 32 The labeling of the X-axis was adapted by us since a typing error inversed the labels in the original report. A HTA conducted by the Canadian Medical Advisory Secretariat (Toronto) in 2005 evaluated the same studies and came to similar conclusions, mainly that the studies are too small and that new and well-conducted RCTs are likely to change these estimates. 56, 57 The HAS and the IECS assessments, 37, 38 and also the MSAC 2003 report come to similar conclusions as to the availability of evidence. 54 In 2006, Löndahl et al. described the design of a single centre RCT to investigate efficacy of HBOT in Sweden that will include 100 patients with diabetic foot ulcers. 18 A narrative review from Räkel et al. for the Canadian Diabetes Association about diabetic foot also summarized many of the findings. 58 Within the COST B14 program (see before), a European RCT for HBOT in the treatment of foot lesions in diabetic patients (study co-ordinator: D. Mathieu, Lille, France) has started in May 2002. In 2005 it was reported that 10 centres were participating and that 56 patients had been included. 42 However, no results have been found.
Page 1 and 2: Hyperbare Zuurstoftherapie: Rapid A
Page 3 and 4: Hyperbare Zuurstoftherapie: Rapid A
Page 5 and 6: KCE Reports 74A Hyperbare Zuurstoft
Page 7 and 8: KCE Reports 74A Hyperbare Zuurstoft
Page 9: KCE Reports 74A Hyperbare Zuurstoft
Page 12 and 13: 2 Hyperbaric Oxygenation Therapy KC
Page 20 and 21: 10 Hyperbaric Oxygenation Therapy K
Page 88 and 89:
78 Hyperbaric Oxygenation Therapy K
Page 90 and 91:
Page 92 and 93:
Page 94 and 95:
Page 96 and 97:
Page 98 and 99:
Page 100 and 101:
KCE Reports 74 Hyperbaric Oxygenati
Page 102 and 103:
Page 104 and 105:
Page 106 and 107:
Page 108 and 109:
Page 110 and 111:
Page 112 and 113:
Page 114 and 115:
Page 116 and 117:
Page 118 and 119:
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Wettelijk depot : D/2008/10.273/13
Page 132:
38. Baarmoederhalskankerscreening e
show all

Hyperbare Zuurstoftherapie: Rapid Assessment - KCE

Create successful ePaper yourself

Delete template?

Save as template?